Skip to main content
. 2021 Dec 29;14(1):76. doi: 10.3390/pharmaceutics14010076

Figure 8.

Figure 8

(a) Comparison of the control group (normal gingiva), periodontitis group and group treated with bromelain 15 mg/kg (arrow shows the first molar and the letter T shows the tongue). Group treated with bromelain indicates improvement of gingival papilla staining, reduction in edema, absence of bleeding and moderate bone loss (Reproduced with permission from [111], John Wiley and Sons, Hoboken, NJ, USA, 2020); (b) morphometric analyses of alveolar bone height; * p < 0.05 indicates the Periodontitis groups versus the Control group and # p < 0.05 indicates the Periodontitis groups versus the Bromelain group (Reproduced with permission from [111], John Wiley and Sons, Hoboken, NJ, USA, 2020); (c) the scheme of the SPRA-bromelain suggested a mechanism of ECM-degradation in pancreatic cancer (Reproduced with permission from [121], ACS Publications, Washington, DC, USA, 2020).